Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... recurrent disease (increased bone marrow blasts ) Refractory AML is defined as patients that have not achieved ... (< 5 white blood cell [WBC]/mm^3 and no blasts in cerebrospinal fluid [CSF]) will be eligible Research ...

    Clinical Trial last updated 07/14/2016 - 4:08pm.

  2. Personalized medicine for MDS

    ... who does not require transfusions, has no increase in blasts , nor any poor-risk cytogenetic abnormalities. These patients, ...

    Research Review last updated 05/02/2016 - 9:44am.

  3. Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

    ... cells in the peripheral blood Less than 30% marrow blasts Absence of t(9:22) or BCR-ABL transcript Adequate major ...

    Clinical Trial last updated 07/14/2016 - 3:59pm.

  4. Acute Myeloid Leukemia (AML)

    ... It happens when young abnormal white blood cells called blasts (leukemia cells), begin to fill up the bone marrow , ... new cases diagnosed each year. When people have AML, blasts make copies of themselves quickly. This slows the production of red ...

    Topic section last updated 07/07/2016 - 3:15pm.

  5. Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies

    ... or relapse/ refractory less than or equal to 10% blasts in bone marrow , or aplasia post-therapy. This includes ... in CR, or relapse with less than or equal 10% bone marrow blasts. CML with tyrosine kinase inhibitor failure in chronic or ...

    Clinical Trial last updated 04/29/2016 - 1:33pm.

  6. Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

    ... or Mylotarg) MDS: Patients must have < 10% marrow blasts ; fewer than 10% marrow blasts must be documented by marrow examination within 3 weeks of initiation of ...

    Clinical Trial last updated 04/28/2016 - 2:45pm.

  7. Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

    ... or with myelodysplasia (MDS) with no circulating blasts and with less than 5% blasts in the bone marrow Planned myeloablative conditioning ...

    Clinical Trial last updated 06/06/2016 - 1:36pm.

  8. Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

    ... AML) as documented by the presence of >20% myeloid blasts in the bone marrow Subjects must be 18 years of age and ...

    Clinical Trial last updated 06/13/2016 - 3:24pm.

  9. Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

    ... leukemia or myelodysplasia with no circulating blasts and with less than 5% blasts in the bone marrow . Patients with chronic lymphocytic ...

    Clinical Trial last updated 06/06/2016 - 1:59pm.

  10. Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

    ... criteria21: Relapsed: Bone marrow blasts ≥5%; reappearance of blasts in the blood; development of extramedullary disease Refractory ...

    Clinical Trial last updated 06/06/2016 - 1:30pm.